

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	O. F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,974 08/18/2003		08/18/2003	Martin Michaelis	DEAV20020064US NP	3394
5487	7590	12/07/2006		EXAMINER	
	OEHLER		KWON, BRIAN YONG S		
	AVENTIS JTE 202-20		ART UNIT	PAPER NUMBER	
	DE: D303A		1614		
BRIDGE	WATER, N	J 08807	DATE MAILED: 12/07/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Office Action Cumment	10/642,974	MICHAELIS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Brian S. Kwon	1614				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address				
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES OF THE WAILING DATES OF THE MAILING DATES OF THE MAILING DATES OF THE WAILING DA	ATE OF THIS COMMUNICATION (6) In no event, however, may a reply be time till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on 29 Se	entember 2006					
<i>'</i> —	•	action is non-final.					
3)							
٥,١	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims	,					
4) 🖂	Claim(s) 2-14,16 and 17 is/are pending in the a	application.					
_	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
6) 🗌	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) 2-14, 16 and 17 are subject to restrict	ion and/or election requirement.					
Applicati	on Papers						
9) 🗌 🤈	The specification is objected to by the Examine	r. ·	·				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority u	ınder 35 U.S.C. § 119						
_	Acknowledgment is made of a claim for foreign ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).				
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the prior	ity documents have been receive	ed in this National Stage				
	application from the International Bureau	(PCT Rule 17.2(a)).	•				
* See the attached detailed Office action for a list of the certified copies not received.							
	•						
Attachment			•				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08) Taper No(3)/Mail Date: Notice of Informal Patent Application							
Paper No(s)/Mail Date 6) Other:							

Application/Control Number: 10/642,974

Art Unit: 1614

DETAILED ACTION

1. Upon further consideration, the Examiner issues further restriction requirement (subsequent to the restriction requirement mailed 12/13/2005) below.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 2-14 and 16-17, drawn to a method for treating pain with the compound of the formula (I) when E is N, classified in class 514, subclass 394.
 - II. Claims 2-7, 12-14 and 16-17, drawn to a method for treating pain with the compound of the formula (I) when E is CH, classified in class 514, subclass 415.
 - III. Claims 2-14 and 16-17, drawn to a method for treating pain with the compound of the formula (I) when E is radical, classified in class 514, subclass 419.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from the compound(s) and disease(s), for example (i) (N-[(S)-2-dipheylamino-2-(5-oxo-4,5-dihydro[1,3,4]oxadiazol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide) and (ii) arthritis pain, under the instant claims of the elected Group. Moreover, whatever specific compound and disease are ultimately elected, applicants are required to list all claims readable thereon.

Application/Control Number: 10/642,974

Art Unit: 1614

With the election of a specific exemplified compound, a generic concept will be identified by the examiner as the inventive group for examination.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

Application/Control Number: 10/642,974

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see http://pair-direct.uspto.gov Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Brian Kwon

Primary Patent Examiner AU 1614

Bul